Quality & innovation
Learn about our quality & innovation
Protecting what protects us
Slowing the progression of Chronic Liver Diseases
The liver is central to our overall health, as part of the metabolic system which regulates our protein, fat and sugar metabolism, as well as mineral, vitamin and hormone balances.
When the liver is damaged by disease or malnutrition, the consequences to health can be serious. Chronic liver diseases (CLD) are a significant public health burden worldwide.
This is why Merz Therapeutics remains fully committed to our work in liver care, alongside our core neurology portfolio.
CLD causes a continuous inflammation and degeneration of the liver, eventually leading to liver fibrosis (liver scarring). Scarring can significantly reduce the function of the affected parts of the liver. It can develop into liver cirrhosis, with life-threatening implications.
CLD treatment can prevent aggravation and the development of liver cirrhosis. It is important to treat liver disease as quickly as possible, with an appropriate therapy to limit liver damage, decrease the symptom burden and improve their quality of life.
Hepa-Merz®
(L-ornithine L-aspartate)
Hepa-Merz® combines two amino acids, L-ornithine and L-aspartate (LOLA), as a treatment for people with CLD. These active ingredients occur naturally in the body and play important roles in liver metabolism and detoxification of the blood. Hepa-Merz is especially suitable for patients with insufficient hepatic detoxification (for example from liver cirrhosis).
PIPELINE
A proud history of delivering high-quality treatments that continues today
At Merz Therapeutics, we are developing innovative medicines to improve patient outcomes. We’re focused on specialty neurology, where we are best-placed to make the most difference.
18
recent approvals
> 150
professionals in R&R roles
5
projects in partnership
